Today's Challenges. Tomorrow's Solutions.

Strategic Solutions for Pulmonology That Turn Diagnostics, Infusions & Critical Care Into Margin

Pulmonology economics stretch from the office visit to the ICU, and increasingly ride on high-cost biologics and diagnostics that payers scrutinize hardest. Fulcrum Health Partners advises independent groups, pulmonary & critical care practices, sleep and infusion programs, and PE- and health-system-backed platforms across commercial rate strategy, PFT and bronchoscopy reimbursement, biologic infusion buy-and-bill economics, prior authorization, and payer contracting — converting complex, capital-intensive service lines into durable margin.

Model Your Reimbursement Opportunity → Speak with a Pulmonology Advisor

$2.7B

Reimbursement Opportunity Identified

12,500+

Payer Contracts Reviewed

States Served

350+

Client Engagements

The Pulmonology Reimbursement Landscape

Cognitive work is squeezed. The dollars — and the risk — have moved to what you administer and test.

In pulmonology, the office and ICU visit pays less in real terms every year — while the economics that decide the practice increasingly sit in the drugs you buy and bill, the diagnostics you own, and the authorizations you must win.

Medicare's physician fee schedule carries no automatic inflation update, so the conversion factor erodes evaluation-and-management and critical-care payment against rising labor and overhead. Meanwhile the revenue base has shifted toward technical and ancillary lines — pulmonary function testing, bronchoscopy including EBUS and navigational procedures, and sleep testing — and toward high-cost biologics for severe asthma administered under buy-and-bill, where ASP-based margins are thin and specialty pharmacy is steadily carving volume away.

Every one of these dollars is exposed. Prior authorization gates biologics, advanced imaging, and diagnostics; site-of-service and specialty-pharmacy mandates move infusions off the practice's books; and antifibrotics for interstitial lung disease, home oxygen and DME, and CPAP all sit inside tightening payer policy. The same patient panel can be worth dramatically different amounts depending on how it is coded, contracted, and defended — and that is precisely where Fulcrum works.

Illustrative composition. Replace with your confirmed figures before launch; reflects current CMS/MedPAC methodology and public payer data, 2024–2026.

Revenue Composition by Service Line — Illustrative

Where pulmonology margin sits — and where it is exposed

Net professional & technical revenue

Margin exposed to payer / Rx pressure

Biologic infusions carry the largest revenue but the thinnest, most contested margin. Fulcrum quantifies and defends the full stack.

Automatic inflation update in the Medicare physician fee schedule

>$30K

Typical annual cost per patient for severe-asthma biologics

ASP+6%

Buy-and-bill margin under specialty-pharmacy pressure

Prior authorization on biologics, advanced imaging & diagnostics

Reimbursement Intelligence in Action

Your pulmonology economics, by profile

Fulcrum turns your claims, procedure, and contract data into executive dashboards. Select a profile to explore a sample payer mix and revenue view spanning professional work, diagnostics, procedures, and biologic infusions.

Independent Pulmonology Group · Payer Mix & Revenue Live Sample

Payer Mix (by active patients)

Net Revenue by Payer — Professional vs. Diagnostics, Procedures & Infusions

Professional & E/M net paymentsDiagnostics, procedures & infusion revenue

Illustrative sample dashboard. Fulcrum builds these from your practice-management, claims, procedure, and contract data by CPT/HCPCS, payer, and contract.

The Forces Reshaping Pulmonology Economics

The strategic questions every pulmonology leader now faces

Beyond the fee schedule, these are the dynamics that decide pulmonology margin — and where Fulcrum builds the strategy.

Biologics & Buy-and-Bill Economics

Protecting infusion margin on severe-asthma biologics and ILD antifibrotics as ASP-based payment tightens and payers push volume to specialty pharmacy and white bagging.

Diagnostics, Procedures & Site of Service

Defending PFTs, bronchoscopy (EBUS and navigational), and sleep testing against technical-component cuts, bundling, and shifts to lower-paying sites.

The Declining Conversion Factor

Absorbing annual real-terms cuts to Medicare physician payment — with no automatic inflation update — across E/M and procedural work.

Critical Care, Hospital-Based & Tele-ICU Billing

Capturing professional revenue for inpatient pulmonary and ICU work, including critical-care time, split/shared rules, and tele-ICU coverage arrangements.

Prior Authorization & Administrative Burden

Reducing the administrative tax on biologics, advanced imaging, and diagnostics as CMS prior-authorization reforms reshape payer obligations and timelines.

Consolidation: Health Systems & PE

Competing with — and evaluating alignment against — health-system employment and PE-backed platforms now consolidating pulmonology, sleep, and infusion assets.

Our Pulmonology Advisory Solutions

Advisory organized around the economics you manage

Not a service menu — the reimbursement problems that decide pulmonology margin and enterprise value, and the strategy, analytics, and negotiation capabilities that resolve them.

01 The Challenge — You can't negotiate what you haven't benchmarked

Contract Assessment & Reimbursement Benchmarking

We digitize and normalize every payer contract and fee schedule, then benchmark your pulmonology reimbursement — E/M, critical care, PFTs, bronchoscopy, sleep testing, and biologic infusion buy-and-bill — against Medicare and against market, quantifying exactly where you sit and what the opportunity is worth.

Contract digitization

Fee schedule normalization

% of Medicare benchmarking

E/M & critical-care rate analysis

Diagnostic & procedural benchmarking

ASP / buy-and-bill margin review

Underpayment identification

Revenue opportunity quantification

Contract performance scoring

02 The Challenge — Little leverage one contract at a time

Managed Care Negotiations & Strategy

We build the positioning, data, and negotiation strategy to improve commercial rates, drug-administration and infusion terms, and diagnostic reimbursement across every payer — from renewals to executive payer meetings.

Commercial rate improvement

Infusion & drug-admin terms

MA & Medicaid managed care

Renewals & redlining

Escalation & executive strategy

Network participation strategy

03 The Challenge — Decisions made without modeling the downside

Contract Modeling & Analytics

CPT/HCPCS- and payer-level modeling that turns claims and contracts into scenario analysis, revenue forecasts, and side-by-side contract comparisons — including buy-and-bill vs. specialty-pharmacy economics — your executives can act on.

CPT/HCPCS-level modeling

Scenario & what-if analysis

Buy-and-bill vs. white bagging

Payer mix & revenue forecasting

Fee schedule comparison

Executive Power BI dashboards

04 The Challenge — Negotiating blind to what competitors are paid

Payer Transparency & Market Rate Intelligence

Federal Transparency in Coverage data has transformed the negotiating table. We mine machine-readable rate files to show what competing pulmonology groups are actually paid for visits, procedures, and drug administration — and arm your team with it.

Transparency in Coverage analysis

Competitor rate benchmarking

Market rate positioning

Negotiation preparation

Peer comparison

Commercial opportunity sizing

05 The Challenge — Effort spread evenly across unequal payers

Covered Lives & Market Intelligence

We map covered lives, payer penetration, referral dynamics, and network adequacy across your market so you prioritize the negotiations and service-line investments that move the most margin.

Covered-lives analysis

Payer penetration & market share

Referral & catchment dynamics

Network adequacy leverage

Employer & population trends

Commercial opportunity identification

06 The Challenge — Contract terms that aren't honored

Payer / Provider Disputes & Enforcement

When payers deny biologics, downcode critical care, bundle diagnostics, or delay infusion payment, we lead the interpretation, escalation, and enforcement — turning contractual entitlement into collected revenue.

Contract interpretation

Payment & claims disputes

Downcoding & bundling challenges

Drug & infusion denial appeals

Escalation & executive negotiation

Contract enforcement

07 The Challenge — Earned revenue that never arrives

Underpayment / Overpayment Recovery & Revenue Integrity

Our analytics compare contracts, fee schedules, ASP allowables, and EOB/remittance data to detect variances, quantify recoverable revenue, resolve overpayment exposure, and fix the root cause so leakage stops.

Contract compliance auditing

Underpayment & variance detection

Overpayment & refund exposure

Automated EOB/remit analytics

Recovery & appeals strategy

Revenue integrity programs

Pulmonology Reimbursement Calculator

See what optimized reimbursement is worth across diagnostics and infusions

Model the annual uplift from moving your commercial pulmonology rates — professional and diagnostic testing plus biologic infusion buy-and-bill — toward market and optimized levels, expressed as a percentage of Medicare.

Your inputs

Enter approximate figures — nothing is stored or transmitted.

Annual commercial revenue — professional & diagnostics

Annual biologic infusion (buy-and-bill) revenue

Current commercial rate (% of Medicare)

Optimized commercial rate (% of Medicare) — 125%

Estimated annual reimbursement uplift

Adjust the inputs to model your opportunity.

Per $1M of commercial revenue

3-year cumulative

Directional estimate for discussion only. Models commercial rate improvement across professional, diagnostic, and biologic infusion buy-and-bill revenue; sleep testing, home oxygen/DME, and site-of-service optimization are additive. A Fulcrum analysis models your actual contracts, ASP/buy-and-bill economics, and payer mix.

Client Outcomes

How Fulcrum helps — and what it's worth

Anonymized outcomes from Fulcrum engagements with pulmonology groups, infusion programs, and platforms.

Independent Pulmonology Group

17%

commercial rate improvement

Situation: benchmarking exposed commercial rates well below market on E/M, PFTs, and bronchoscopy. Result: we repositioned the group and renegotiated its top commercial payers, lifting blended reimbursement without adding a single visit or procedure.

Sleep & Infusion Program

$3.9M

infusion margin protected & recovered

Situation: severe-asthma biologic margins were eroding as payers pushed white bagging and denied buy-and-bill claims. Result: we secured favorable drug-administration terms and recovered systematic underpayments, stabilizing infusion economics.

PE-Backed Platform

8 pts

margin from contract harmonization

Situation: a multi-state platform carried a patchwork of legacy contracts and inconsistent infusion terms. Result: we harmonized rates and recovered underpayments across sites, lifting EBITDA ahead of a recapitalization.

Why Pulmonology Leaders Choose Fulcrum

The advisor that speaks pulmonology's economic language

Independent by design and fluent in the economics of the specialty — E/M and critical care, PFTs and bronchoscopy, sleep testing, biologic infusion buy-and-bill, and payer policy — delivered by the people who do the work.

Independent Advisor

No networks, no downstream fees — only your economics.

Pulmonology & Critical Care Fluency

Fluent in the visit, the procedure, and the ICU that fund the practice.

Commercial Rate Benchmarking

Market and transparency data behind every ask.

Diagnostic & Procedural Analytics

Modeling down to the CPT, HCPCS, and infusion line.

National Payer Experience

Insight into payer policy in every market.

Biologic & Buy-and-Bill Insight

ASP, white bagging, and specialty-pharmacy strategy.

Negotiation Leadership

Senior advisors at the table, not junior staff.

Data-Driven Support

Dashboards and intelligence that clarify the path.

Fulcrum Intelligence

Pulmonology insights & analysis

Executive briefings on the forces moving pulmonology economics — the fee schedule, biologic buy-and-bill, diagnostics and site of service, prior authorization, and consolidation.

Defending Biologic Buy-and-Bill Against White Bagging → Protecting PFT, Bronchoscopy & Sleep Reimbursement →

Explore Pulmonology Insights →